MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SLL
Status:
NOT_YET_RECRUITING
Trial end date:
2030-07-30
Target enrollment:
Participant gender:
Summary
This is a single-arm, open-label study of sonrotoclax plus zanubrutinib with MRD-driven treatment duration in patients with previously untreated Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL).
The primary goal of this study is to evaluate the efficacy of MRD-guided zanubrutinib plus sonrotoclax for first-line CLL/SLL treatment.
Phase:
PHASE2
Details
Lead Sponsor:
Institute of Hematology & Blood Diseases Hospital, China